(908) 425-4878


Octapharma Targets Primary Immune Deficiency Research with Grant for The Mount Sinai Medical Center

Published: Jan 18, 2011 | Last modified: Jan 18, 2011
NEW YORK and HOBOKEN, NJ (January 18, 2011) - Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma...

Researchers Propose New Objective Criteria for Evaluating the Treatment of von Willebrand Disease

Published: Dec 14, 2010 | Last modified: Dec 14, 2010
HOBOKEN, NJ (December 8, 2010) - Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease (VWD) and reported on their application of these criteria...

FDA Approves octaplex® for Fast Track Development

Published: Dec 1, 2010 | Last modified: Dec 1, 2010
HOBOKEN, NJ (December 1, 2010) - The U.S. Food and Drug Administration (FDA) has approved Octapharma USA's Investigational New Drug Application for octaplex® (Human Prothrombin Complex, Freeze Dried) as a Fast Track Product for "Reversal of Anticoag...

Octapharma Supports VWD Educational Initiatives Launched at Hemophilia Foundation Annual Meeting

Published: Nov 9, 2010 | Last modified: Nov 9, 2010
HOBOKEN, NJ - Octapharma USA is proud to support educational initiatives for von Willebrand Disease (VWD), the most common inherited bleeding disorder, at the 62nd Annual Meeting of the National Hemophilia Foundation (NHF) scheduled for Nov. 11-13 in...

Hemophilia A Clinical Trial Starts: First Recombinant Factor VIII Derived from a Human Cell-Line

Published: Nov 1, 2010 | Last modified: Nov 1, 2010
HOBOKEN, N.J. (November 1, 2010) - Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study...

Octapharma USA Accepting Applications for Research Grants Focused on Human Protein Therapies

Published: Oct 27, 2010 | Last modified: Oct 27, 2010
HOBOKEN, NJ (October 27, 2010) - Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy...

Cortes & Hay Attorney Assist Program Streamlines Real Estate Transactions for Home Buyers & Sellers

Published: Oct 25, 2010 | Last modified: Oct 25, 2010
FLEMINGTON, N.J. (October 25, 2010) - The Department of Housing and Urban Development (HUD) has significantly changed its requirements for real estate closings, adding to the complexity of property transactions and prompting Cortes & Hay, Inc. of Fle...
© Yankee Public Relations 2019 - powered by EggZack